Issei Oi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Issei Oi has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Kohei Fujita
National Hospital Organization Kyoto Medical Center
11 shared publications Takanori Ito
Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Kyoto Japan
11 shared publicationsOsamu Kanai
Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Kyoto Japan
8 shared publicationsNaoki Fujimoto
Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Kyoto Japan
7 shared publicationsSaiki Yoshimura
Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Kyoto Japan
7 shared publications- Isao Ito
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan; Department of Respiratory Medicine, Graduate School of Medicine, Gunma University, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (12) , e70328
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management
Background: Osimertinib is the standard first‐line treatment for epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung cancer (NSCLC). However, the impact of dose‐reduction on survival and the role of post‐progression management in real‐world settings remain unclear. Methods: We conducted a multi‐institutional retrospective cohort study on patients with EGFR‐mutated advanced NSCLC who received first‐line osimertinib between January 2018 and December 2023. Patients were classified into dose‐reduced and full‐dose groups. Primary endpoints were time to treatment failure (TTF) and overall survival (OS). The subsequent treatment after progression was also exploratively assessed to evaluate the impact of initial dose modification on the entire treatment sequence. Results: A total of 90 patients were analyzed, consisting of 61 patients in the full‐dose group and 29 in the dose‐reduction group. Median follow‐up was 21.5 months (IQR 9.1–37.2). The dose‐reduced group had significantly worse baseline performance status (PS) (PS 2–3: 37.9% vs. 14.8%, p = 0.014). Despite this, dose reduction showed no significant impact on TTF (adjusted HR 0.66, 95% CI 0.40–1.10, p = 0.11) or OS (HR 0.97, 95% CI 0.59–1.58, p = 0.89). Multivariate analysis revealed that transition to best supportive care (BSC) after progression, rather than initial dose reduction, was associated with OS (hazard ratio, 7.40; p < 0.0001). The proportions of patients receiving subsequent chemotherapy were comparable between the groups. Conclusions: Osimertinib dose reduction in the first‐line setting was not associated with inferior OS, suggesting that appropriate dose modification helps maintain PS. Transition to BSC after progression, rather than initial dose intensity, was associated with poor prognosis.
- 17 June 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (12) , e70328
Open AccessAssociation Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management
Background: Osimertinib is the standard first‐line treatment for epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung cancer (NSCLC). However, the impact of dose‐reduction on survival and the role of post‐progression management in real‐world settings remain unclear. Methods: We conducted a multi‐institutional retrospective cohort study on patients with EGFR‐mutated advanced NSCLC who received first‐line osimertinib between January 2018 and December 2023. Patients were classified into dose‐reduced and full‐dose groups. Primary endpoints were time to treatment failure (TTF) and overall survival (OS). The subsequent treatment after progression was also exploratively assessed to evaluate the impact of initial dose modification on the entire treatment sequence. Results: A total of 90 patients were analyzed, consisting of 61 patients in the full‐dose group and 29 in the dose‐reduction group. Median follow‐up was 21.5 months (IQR 9.1–37.2). The dose‐reduced group had significantly worse baseline performance status (PS) (PS 2–3: 37.9% vs. 14.8%, p = 0.014). Despite this, dose reduction showed no significant impact on TTF (adjusted HR 0.66, 95% CI 0.40–1.10, p = 0.11) or OS (HR 0.97, 95% CI 0.59–1.58, p = 0.89). Multivariate analysis revealed that transition to best supportive care (BSC) after progression, rather than initial dose reduction, was associated with OS (hazard ratio, 7.40; p < 0.0001). The proportions of patients receiving subsequent chemotherapy were comparable between the groups. Conclusions: Osimertinib dose reduction in the first‐line setting was not associated with inferior OS, suggesting that appropriate dose modification helps maintain PS. Transition to BSC after progression, rather than initial dose intensity, was associated with poor prognosis.
- Open Access
- 28 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Bronchoscopic removal of lower airway foreign body: a two-center retrospective cohort study
Background: Tracheobronchial foreign body (FB) aspiration is a life-threatening condition, particularly in older adults. Despite its clinical significance, research on the etiology of adult FB aspiration, as well as real-world outcomes and complications associated with FB removal in lower airways, remains limited. Patients and methods: This was a two-center retrospective cohort study in Japan. We included adult patients aged 18 years or older who underwent bronchoscopic FB removal between April 2010 and March 2025. Results: A total of 28 patients were included in this analysis (mean age, 75.4 years [median age: 75 years]; range, 55–102 years). Nineteen patients (67.9%) were male. The most frequently reported symptoms were coughing (46.4%), sputum production (39.3%), and dyspnea (17.9%). A total of 30 FBs were identified, with dental prostheses (60.0%) being the most common type, followed by natural teeth (10.0%). FBs were slightly more common on the right side (53.3%) than on the left side (43.3%), with the right lower lobe being the most frequent site of lodgement (30.0%), followed by the left lower lobe (20.7%). The most frequently bronchoscopic findings were mucosal edema (36.7%) and bleeding (26.7%). FB removal was performed using flexible bronchoscopy in 26 patients (92.9), with the exception of two cases (7.1%) in which rigid bronchoscopy was employed. Bronchoscopy was performed in the endoscopy room for 21 patients (75.0%). Among the 28 patients, standard forceps were used in 24 (85.7%), followed by basket forceps, which was employed in 10 patients (35.7%). FB removal was successful in 26 (92.9%) patients. Regarding adverse events, hypoxia was the only complication observed, occurring in 18 patients (64.3%); no other adverse events were reported. Conclusions: Most FB in the lower airways can be successfully and safely removed via flexible bronchoscopy.
- 28 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessBronchoscopic removal of lower airway foreign body: a two-center retrospective cohort study
Background: Tracheobronchial foreign body (FB) aspiration is a life-threatening condition, particularly in older adults. Despite its clinical significance, research on the etiology of adult FB aspiration, as well as real-world outcomes and complications associated with FB removal in lower airways, remains limited. Patients and methods: This was a two-center retrospective cohort study in Japan. We included adult patients aged 18 years or older who underwent bronchoscopic FB removal between April 2010 and March 2025. Results: A total of 28 patients were included in this analysis (mean age, 75.4 years [median age: 75 years]; range, 55–102 years). Nineteen patients (67.9%) were male. The most frequently reported symptoms were coughing (46.4%), sputum production (39.3%), and dyspnea (17.9%). A total of 30 FBs were identified, with dental prostheses (60.0%) being the most common type, followed by natural teeth (10.0%). FBs were slightly more common on the right side (53.3%) than on the left side (43.3%), with the right lower lobe being the most frequent site of lodgement (30.0%), followed by the left lower lobe (20.7%). The most frequently bronchoscopic findings were mucosal edema (36.7%) and bleeding (26.7%). FB removal was performed using flexible bronchoscopy in 26 patients (92.9), with the exception of two cases (7.1%) in which rigid bronchoscopy was employed. Bronchoscopy was performed in the endoscopy room for 21 patients (75.0%). Among the 28 patients, standard forceps were used in 24 (85.7%), followed by basket forceps, which was employed in 10 patients (35.7%). FB removal was successful in 26 (92.9%) patients. Regarding adverse events, hypoxia was the only complication observed, occurring in 18 patients (64.3%); no other adverse events were reported. Conclusions: Most FB in the lower airways can be successfully and safely removed via flexible bronchoscopy.
- Open Access
- 3 February 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Safety and Efficacy of CT-Guided Lung Biopsy in Elderly Patients age 75 Years and Older: A Single-Centre Retrospective Comparative Study
Introduction: CT-guided biopsy has good diagnostic accuracy, but adverse events such as pneumothorax are common. There are few reports on the safety and efficacy of CT-guided biopsy in the elderly. Methods: This was a retrospective single-centre cohort study. Patients who underwent CT-guided lung biopsy between February 2017 and August 2024 were included. Patient background, disease background, examination status, and adverse events were ascertained. Elderly were defined as those aged 75 years and older. The primary outcome was the incidence of all adverse events, and the secondary outcomes were the incidence of pneumothorax and diagnostic accuracy. Categorical variables were compared by Chi-square test, and continuous variables by t-test. Multivariable analysis was performed by logistic regression analysis adjusted for age, sex, lung comorbidities, and radiological findings of target lesion. Results: There were significant differences between the two groups in ECOG-PS and the distance from the surface to pleura and target. In the primary outcome, any adverse events occurred in 207 patients (56.2%), with no significant difference between elderly (97/180, 53.9%) and non-elderly (110/188, 58.5%) patients ( p = 0.401). Pneumothorax was the most common adverse event, occurring in 151 (41.0%) patients, with no significant difference between elderly (68/180, 37.8%) and non-elderly (83/188, 44.1%) ( p = 0.244). On multivariate analysis, elderly (75years or older) was not clearly associated with the occurrence of all or severe adverse events, pneumothorax, and confirmed diagnosis. Location in the lower lung field and distant from the pleura were significantly associated with the incidence of all adverse event. In the secondary outcomes, emphysema or interstitial pneumonia, location in the lower lung field, and distant from the pleura were significantly associated with pneumothorax. There was no significant difference in the diagnostic accuracy disease between the elderly and non-elderly patients. Conclusions: The incidence of adverse events and diagnostic accuracy of CT-guided biopsy are similar in elderly and non-elderly patients, and this method is useful even in elderly patients. Key point The safety and efficacy of CT-guided lung biopsy in elderly patients are equivalent to those in non-elderly patients.
- 3 February 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Open AccessSafety and Efficacy of CT-Guided Lung Biopsy in Elderly Patients age 75 Years and Older: A Single-Centre Retrospective Comparative Study
Introduction: CT-guided biopsy has good diagnostic accuracy, but adverse events such as pneumothorax are common. There are few reports on the safety and efficacy of CT-guided biopsy in the elderly. Methods: This was a retrospective single-centre cohort study. Patients who underwent CT-guided lung biopsy between February 2017 and August 2024 were included. Patient background, disease background, examination status, and adverse events were ascertained. Elderly were defined as those aged 75 years and older. The primary outcome was the incidence of all adverse events, and the secondary outcomes were the incidence of pneumothorax and diagnostic accuracy. Categorical variables were compared by Chi-square test, and continuous variables by t-test. Multivariable analysis was performed by logistic regression analysis adjusted for age, sex, lung comorbidities, and radiological findings of target lesion. Results: There were significant differences between the two groups in ECOG-PS and the distance from the surface to pleura and target. In the primary outcome, any adverse events occurred in 207 patients (56.2%), with no significant difference between elderly (97/180, 53.9%) and non-elderly (110/188, 58.5%) patients ( p = 0.401). Pneumothorax was the most common adverse event, occurring in 151 (41.0%) patients, with no significant difference between elderly (68/180, 37.8%) and non-elderly (83/188, 44.1%) ( p = 0.244). On multivariate analysis, elderly (75years or older) was not clearly associated with the occurrence of all or severe adverse events, pneumothorax, and confirmed diagnosis. Location in the lower lung field and distant from the pleura were significantly associated with the incidence of all adverse event. In the secondary outcomes, emphysema or interstitial pneumonia, location in the lower lung field, and distant from the pleura were significantly associated with pneumothorax. There was no significant difference in the diagnostic accuracy disease between the elderly and non-elderly patients. Conclusions: The incidence of adverse events and diagnostic accuracy of CT-guided biopsy are similar in elderly and non-elderly patients, and this method is useful even in elderly patients. Key point The safety and efficacy of CT-guided lung biopsy in elderly patients are equivalent to those in non-elderly patients.
- Open Access
- 5 January 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (1)
Reconsidering the Role of Blood Cultures in Community‐Acquired Pneumonia: A Case of Co‐Infection With Streptococcus pneumoniae and Klebsiella variicola
Community‐acquired pneumonia ( CAP ) remains a leading cause of morbidity and mortality. Streptococcus pneumoniae is the most common causative pathogen, with urinary antigen testing aiding the diagnosis thereof; however, blood culture yields are low, and guideline recommendations vary. We herein report a case of a 77‐year‐old man with pneumococcal pneumonia confirmed by urinary antigen testing whose blood cultures also revealed Klebsiella variicola . The detection of this co‐infection would have been missed without blood cultures. Moreover, this combination of pathogens is first reported. This case underscores the importance of routine blood cultures in CAP diagnosis and supports the Japanese Respiratory Society's recommendation for their use in hospitalised patients.
- 5 January 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (1)
Open AccessReconsidering the Role of Blood Cultures in Community‐Acquired Pneumonia: A Case of Co‐Infection With Streptococcus pneumoniae and Klebsiella variicola
Community‐acquired pneumonia ( CAP ) remains a leading cause of morbidity and mortality. Streptococcus pneumoniae is the most common causative pathogen, with urinary antigen testing aiding the diagnosis thereof; however, blood culture yields are low, and guideline recommendations vary. We herein report a case of a 77‐year‐old man with pneumococcal pneumonia confirmed by urinary antigen testing whose blood cultures also revealed Klebsiella variicola . The detection of this co‐infection would have been missed without blood cultures. Moreover, this combination of pathogens is first reported. This case underscores the importance of routine blood cultures in CAP diagnosis and supports the Japanese Respiratory Society's recommendation for their use in hospitalised patients.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 9328618
A Case of Miliary Tuberculosis Complicated by Knee Joint Tuberculosis
This case report details a 75‐year‐old male diagnosed with miliary tuberculosis (TB) who subsequently developed tuberculous arthritis in his left knee. The patient was initially admitted for a hemorrhagic gastric ulcer, where chest imaging and positive cultures from multiple sites confirmed miliary TB. Standard antitubercular therapy was started, but 6 weeks later, he presented with worsening pain and swelling in his left knee. A joint aspiration and MRI confirmed tuberculous arthritis with an abscess, which necessitated surgical debridement in addition to the drug regimen. We emphasize that orthopaedic TB often requires surgical intervention alongside medication for successful treatment. While total knee arthroplasty can be an effective treatment for joint destruction, the previous report suggests that it should be delayed until after a prolonged course of antitubercular therapy (e.g., 12 months or more) to prevent recurrence.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 9328618
Open AccessA Case of Miliary Tuberculosis Complicated by Knee Joint Tuberculosis
This case report details a 75‐year‐old male diagnosed with miliary tuberculosis (TB) who subsequently developed tuberculous arthritis in his left knee. The patient was initially admitted for a hemorrhagic gastric ulcer, where chest imaging and positive cultures from multiple sites confirmed miliary TB. Standard antitubercular therapy was started, but 6 weeks later, he presented with worsening pain and swelling in his left knee. A joint aspiration and MRI confirmed tuberculous arthritis with an abscess, which necessitated surgical debridement in addition to the drug regimen. We emphasize that orthopaedic TB often requires surgical intervention alongside medication for successful treatment. While total knee arthroplasty can be an effective treatment for joint destruction, the previous report suggests that it should be delayed until after a prolonged course of antitubercular therapy (e.g., 12 months or more) to prevent recurrence.
- Open Access
- 19 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26
Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study
The optimal management of patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) after progression on osimertinib includes cytotoxic chemotherapy. Continuing osimertinib therapy beyond progressive disease (PD) is occasionally adopted in real-world practice; however, evidence for its efficacy is limited. In this multi-institutional retrospective study, we evaluated whether osimertinib continuation beyond PD could improve survival compared with the best supportive care (BSC) in such patients. We retrospectively reviewed patients with EGFR-mutated advanced or recurrent NSCLC treated with osimertinib between March 2016 and September 2025 at three Japanese community hospitals. Patients with radiological progression or intolerable adverse events after osimertinib treatment were included Patients were classified into three groups: (1) osimertinib beyond PD, (2) BSC, and (3) chemotherapy after osimertinib. Overall survival (OS) was compared among the groups using Kaplan-Meier and Cox regression analyses adjusted for time-to-treatment failure (TTF). Of the 309 patients treated with osimertinib, 126 met the inclusion criteria. The median age of the patients was 77 years, and 23% had poor performance status (≥ 2). Osimertinib beyond PD was administered to 21 patients (16.7%), BSC to 36 patients (28.6%), and chemotherapy to 69 patients (54.8%). The median OS after osimertinib failure was 8.8, 2.6, and 15.5 months in the beyond PD, BSC, and chemotherapy groups, respectively (p < 0.001). In multivariate analysis, beyond PD was associated with significantly longer OS than BSC (hazard ratio: 0.34, 95% confidence interval: 0.18-0.66, p < 0.001), even after adjusting for TTF. In real-world settings involving elderly and frail patients, osimertinib continuation beyond PD was associated with improved survival compared with BSC alone. Although chemotherapy remains the preferred strategy when feasible, osimertinib continuation beyond PD may represent a reasonable treatment option for patients who are ineligible for further cytotoxic therapy. In the absence of other guiding biomarkers, TTF may help clinicians identify patients most likely to benefit from continued TKI administration.
- 19 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26
Open AccessClinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study
The optimal management of patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) after progression on osimertinib includes cytotoxic chemotherapy. Continuing osimertinib therapy beyond progressive disease (PD) is occasionally adopted in real-world practice; however, evidence for its efficacy is limited. In this multi-institutional retrospective study, we evaluated whether osimertinib continuation beyond PD could improve survival compared with the best supportive care (BSC) in such patients. We retrospectively reviewed patients with EGFR-mutated advanced or recurrent NSCLC treated with osimertinib between March 2016 and September 2025 at three Japanese community hospitals. Patients with radiological progression or intolerable adverse events after osimertinib treatment were included Patients were classified into three groups: (1) osimertinib beyond PD, (2) BSC, and (3) chemotherapy after osimertinib. Overall survival (OS) was compared among the groups using Kaplan-Meier and Cox regression analyses adjusted for time-to-treatment failure (TTF). Of the 309 patients treated with osimertinib, 126 met the inclusion criteria. The median age of the patients was 77 years, and 23% had poor performance status (≥ 2). Osimertinib beyond PD was administered to 21 patients (16.7%), BSC to 36 patients (28.6%), and chemotherapy to 69 patients (54.8%). The median OS after osimertinib failure was 8.8, 2.6, and 15.5 months in the beyond PD, BSC, and chemotherapy groups, respectively (p < 0.001). In multivariate analysis, beyond PD was associated with significantly longer OS than BSC (hazard ratio: 0.34, 95% confidence interval: 0.18-0.66, p < 0.001), even after adjusting for TTF. In real-world settings involving elderly and frail patients, osimertinib continuation beyond PD was associated with improved survival compared with BSC alone. Although chemotherapy remains the preferred strategy when feasible, osimertinib continuation beyond PD may represent a reasonable treatment option for patients who are ineligible for further cytotoxic therapy. In the absence of other guiding biomarkers, TTF may help clinicians identify patients most likely to benefit from continued TKI administration.
- Open Access
- 16 December 2025
- Published by Springer Nature in BMC Research Notes
- Vol. 19 (1)
Single-centre retrospective experience of complications and outcomes of computed tomography-guided lung biopsy and interventions for the management of intrathoracic infections
Objective: To investigate the complications and outcomes of computed tomography (CT)-guided lung biopsy and interventions in the management of intrathoracic infections. Results: Twenty-nine patients were examined. Eleven (37.9%) patients were diagnosed with pulmonary nodules, and 18 (62.1%) underwent drainage of lung abscesses. The median age of the patients was 77 years, and 44.8% had a poor performance status. The major underlying diseases were hypertension and malignancies. The puncture site was mostly the right lower lobe (44.8%), whereas there were no cases of puncture in the left upper lobe. The nodule diagnostic success rate was 54.5% and the success rate of lung abscess drainage was 88.9%. The common organisms identified were Aspergillus , S. pneumoniae and S. aureus in the nodules and S. intermedius in the lung abscess drainage. Pigtail catheters were most commonly used for drainage (50%). Pneumothorax and hypoxaemia were the most common adverse events (13.8%), followed by fever (10.3%). Clinical trial registration : This retrospective study was registered in the UMIN Clinical Trials Registry (registration No. UMIN000055755). This clinical trial was registered on 6 October 2024 and is publicly available.
- 16 December 2025
- Published by Springer Nature in BMC Research Notes
- Vol. 19 (1)
Open AccessSingle-centre retrospective experience of complications and outcomes of computed tomography-guided lung biopsy and interventions for the management of intrathoracic infections
Objective: To investigate the complications and outcomes of computed tomography (CT)-guided lung biopsy and interventions in the management of intrathoracic infections. Results: Twenty-nine patients were examined. Eleven (37.9%) patients were diagnosed with pulmonary nodules, and 18 (62.1%) underwent drainage of lung abscesses. The median age of the patients was 77 years, and 44.8% had a poor performance status. The major underlying diseases were hypertension and malignancies. The puncture site was mostly the right lower lobe (44.8%), whereas there were no cases of puncture in the left upper lobe. The nodule diagnostic success rate was 54.5% and the success rate of lung abscess drainage was 88.9%. The common organisms identified were Aspergillus , S. pneumoniae and S. aureus in the nodules and S. intermedius in the lung abscess drainage. Pigtail catheters were most commonly used for drainage (50%). Pneumothorax and hypoxaemia were the most common adverse events (13.8%), followed by fever (10.3%). Clinical trial registration : This retrospective study was registered in the UMIN Clinical Trials Registry (registration No. UMIN000055755). This clinical trial was registered on 6 October 2024 and is publicly available.
- 8 August 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (9) , 102789
Incidence of and risk factors for side effects associated with antibiotic treatment for pneumonia
- 8 August 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (9) , 102789
Incidence of and risk factors for side effects associated with antibiotic treatment for pneumonia
- Open Access
- 23 July 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (7) , e70287
A Case of Haemophilus influenzae Colonisation in Bronchiectasis Following COVID‐19: Post‐COVID‐19 Bronchiectasis as a Structural Hotbed for Chronic Airway Infections
Coronavirus Disease 2019 (COVID‐19) can lead to respiratory sequelae, including bronchiectasis. While bronchiectasis following tuberculosis is a breeding ground for many bacterial infections/colonisation, there are few reports of bronchiectasis following COVID‐19 being a hotbed for bacterial infection/colonisation. We present a case of a 69‐year‐old female who developed bronchiectasis following COVID‐19 pneumonia. The patient had no abnormal findings on chest CT scan for 5 years before COVID‐19. She developed persistent cough and sputum after COVID‐19 and chest CT just after COVID‐19 revealed new bronchiectasis. One year later, she was introduced to our department for repeating exacerbation of chronic respiratory infection, and Haemophilus influenzae was detected in sputum. This case highlights the potential for H. influenzae to infect/colonise in post‐COVID‐19 bronchiectasis. While there have been few reports of chronic airway infection complicating bronchiectasis after COVID‐19 until now, long‐term respiratory follow‐up and management of bacterial colonisation are crucial in these patients in the future. This case suggests that COVID‐19 can predispose individuals to bacterial infection in the setting of bronchiectasis, emphasising the need for vigilance in post‐COVID‐19 airway management.
- 23 July 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (7) , e70287
Open AccessA Case of Haemophilus influenzae Colonisation in Bronchiectasis Following COVID‐19: Post‐COVID‐19 Bronchiectasis as a Structural Hotbed for Chronic Airway Infections
Coronavirus Disease 2019 (COVID‐19) can lead to respiratory sequelae, including bronchiectasis. While bronchiectasis following tuberculosis is a breeding ground for many bacterial infections/colonisation, there are few reports of bronchiectasis following COVID‐19 being a hotbed for bacterial infection/colonisation. We present a case of a 69‐year‐old female who developed bronchiectasis following COVID‐19 pneumonia. The patient had no abnormal findings on chest CT scan for 5 years before COVID‐19. She developed persistent cough and sputum after COVID‐19 and chest CT just after COVID‐19 revealed new bronchiectasis. One year later, she was introduced to our department for repeating exacerbation of chronic respiratory infection, and Haemophilus influenzae was detected in sputum. This case highlights the potential for H. influenzae to infect/colonise in post‐COVID‐19 bronchiectasis. While there have been few reports of chronic airway infection complicating bronchiectasis after COVID‐19 until now, long‐term respiratory follow‐up and management of bacterial colonisation are crucial in these patients in the future. This case suggests that COVID‐19 can predispose individuals to bacterial infection in the setting of bronchiectasis, emphasising the need for vigilance in post‐COVID‐19 airway management.
- Open Access
- 24 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-4
Mycobacterium avium (MAC) lung disease in post-COVID-19 bronchiectasis: a need for caution as a potential risk factor for MAC infection
Bronchiectasis due to previous tuberculosis is known to precede Mycobacterium avium (MAC) lung disease. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, and residual bronchiectasis following COVID-19 is common as well as tuberculosis. However, there have been no reports documenting MAC lung disease secondary to bronchiectasis post-COVID-19 until now. We present the case of an 84-year-old patient on steroid therapy for alveolar hemorrhage who developed COVID-19, resulting in residual bronchiectasis. Despite no evidence of chronic airway infection immediately prior to the COVID-19 infection, the patient developed pulmonary MAC disease 2 years later. This is the first report of MAC lung disease secondary to bronchiectasis following COVID-19. Similar cases are likely to occur in the future, necessitating caution.
- 24 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-4
Open AccessMycobacterium avium (MAC) lung disease in post-COVID-19 bronchiectasis: a need for caution as a potential risk factor for MAC infection
Bronchiectasis due to previous tuberculosis is known to precede Mycobacterium avium (MAC) lung disease. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, and residual bronchiectasis following COVID-19 is common as well as tuberculosis. However, there have been no reports documenting MAC lung disease secondary to bronchiectasis post-COVID-19 until now. We present the case of an 84-year-old patient on steroid therapy for alveolar hemorrhage who developed COVID-19, resulting in residual bronchiectasis. Despite no evidence of chronic airway infection immediately prior to the COVID-19 infection, the patient developed pulmonary MAC disease 2 years later. This is the first report of MAC lung disease secondary to bronchiectasis following COVID-19. Similar cases are likely to occur in the future, necessitating caution.